Back to Results


Title A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action Ruxolitinib Cream for Vitiligo (TRuE-V MOA)
Therapeutic Area Vitiligo
Principal Investigator David Rosmarin, MD
Min Age 18 Years
Gender Any
Contact Nicole Dumont
More Information


To evaluate the change in immune biomarkers in participants with vitiligo

Study Details

Inclusion Criteria

  • A clinical diagnosis of non-segmental vitiligo with depigmented areas including  ≥ 0.5% BSA on the face,  ≥ 0.5 F-VASI,  ≥ 3% BSA on non-facial areas, and  ≥ 3 T-VASI
  • Total body vitiligo area (facial and non-facial) should not exceed 50% BSA
  • At least 1 active vitiligo lesion (e.g. such as confetti lesion, trichrome appearance, pinkish rim, or other evidence of inflammatory activity) at the site for skin biopsy

Exclusion Criteria

  • No pigmented hair within any of the vitiligo areas on the face
  • Used depigmentation treatments (e.g. monobenzone) for past treatment with vitiligo or other pigmented areas

Study Requirements

Screening is up to 42 days (~6 weeks); the double-blind, vehicle-controlled treatment period is 24 weeks; the open-label treatment extension period is 28 weeks; and safety follow-up is 30 days. Total duration is up to approximately 63 weeks